Key design criteria of the analysis
| Population | Individuals newly diagnosed with CRC and FDR and SDR |
| Intervention | DNA sequencing of all newly diagnosed CRC cases and cascade genetic testing of four or more FDR and SDR of identified LS cases |
| Comparator | Current strategy with IHC, BRAF V600E and DNA sequencing for a proportion of newly diagnosed CRC cases and cascade testing of four FDR and/or SDR |
| Outcome | QALYs saved |
| Model type | Decision trees integrated with Markov models |
| Time horizon | Lifetime/50 years |
| Perspective | Swiss healthcare system |
| Costs | Swiss francs (CHF) |
| Discounting | 3% per year |
| Cost-effectiveness threshold | CHF100000 per QALY |
CRC, colorectal cancer; FDR, first-degree relative; IHC, immunohistochemistry; LS, Lynch syndrome; QALYs, quality-adjusted life years; SDR, second-degree relative.